Incorporating Biosimilar Insulin in the Pharmacy: Updates on Interchangeability and the Role of the Pharmacist (Pharmacist Credit)

Add-on activity

This activity includes patient counseling videos.

Program Description

While to date there are a few insulin biosimilars approved for use in patients with diabetes and some undergoing clinical trials, the approval of the first interchangeable insulin biosimilar is an important step in improving access and reducing costs of diabetes management for patients. Pharmacists and pharmacy technicians must be familiar with FDA guidance regarding interchangeability and how the new insulin biosimilar will affect their practice. This program will explore the development, regulatory pathway and approval process, and safety and efficacy considerations for the use of the currently available interchangeable insulin biosimilar in diabetes management. As the role of biosimilars in the care of patients with diabetes continues to expand, pharmacists and pharmacy technicians will be valuable sources of information about these agents and will need to increase awareness about their use among prescribers and patients. This activity includes counseling videos that will cover important counseling pearls for pharmacists to educate health care providers as well as patients on the proper use and role of interchangeable insulin formulations in diabetes treatment and management to improve outcomes and access to care.

Target audience: Retail pharmacists

Type of activity: Application for pharmacists; Knowledge for technicians
Release date: May 31, 2022
Expiration date: May 31, 2023

Time to complete activity: 2 hours
Fee: Free

Educational Objectives

At the completion of this activity, pharmacists will be able to:

• Analyze the regulations and approval pathways for biologics and biosimilars
• Explain requirements for an interchangeable biosimilar
• Explore advancements of insulin biosimilars in reducing barriers affecting insulin use, access, and adherence for patients with diabetes
• Identify the role of the pharmacist in addressing patient barriers with insulin treatment and counseling on newest available treatment options

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity numbers 0290-0000-22-264-H01-P and 0290-0000-22-265-H01-T. The activity is available for CE credit through May 31, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Sneha Baxi Srivastava, PharmD, BCACP, CDCES, DipACLM

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, MBA, CHCP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta

Pharmacy Times® Editorial Staff—Davy James

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms